In 2017 Avanos Medical was formed after completing its spinoff from consumer giant Kimberly Clark and divesting its Surgical & Infection Prevention business . After five plus years of acquisitions, responses to unmet industry needs and the needs to heighten focus on commercial execution and increase production in the midst of the global COVID-19 pandemic, Avanos is now an industry leading pure play medical device company.
What does a successful, seismic shift in healthcare business strategy and execution take? What can it mean for life science innovators and their investors? What made it possible?
For investors – How is Avanos delivering on its growth potential?
For both early and later stage companies? How is Avanos leveraging Open Innovation and M+A to help drive our growth objectives?
Find out during Avanos CEO Joe Woody’s lunch conversation moderated by HealthQuest Capital’s Tom Callaway at Southeast Life Science’s AdvanSE 2022 on Wednesday, May 25, 2022.
Register today for our flagship event that connects innovative life sciences companies and trailblazing researchers in front of accomplished investors and corporations that want to do business with them.
“By attending AdvanSE, I get to meet some of the leading entrepreneurs and interesting companies in the Southeast. AdvanSE offers exclusive opportunities to network with other investors and strategics and is the one-stop shop for innovation in the region.” – Kyp Sirinakis, Co-Founder and Managing Partner, Epidarex Capital
In just 48 hours at AdvanSE, investors, innovators, universities and solution providers can see the very best of what the southeast life sciences innovation ecosystem has to offer. The highly efficient “shopping” of the investors, corporate partners, and companies that attend our events helps the critical mass of innovators in the region further their ingenuity through partnerships and investment.
Joseph F. Woody, CEO, Avanos
As chief executive officer and member of the board of directors, Joe Woody brings 20 years of healthcare leadership experience and proven success driving revenue growth and expertise in spearheading portfolio transformations.
Prior to joining the company in 2017, Joe served as chief executive officer and president of Acelity, where he was responsible for overseeing the development and commercialization of their innovative wound care and regenerative medicine business. He also served as global president, vascular therapies, for Covidien, creating their vascular division and leading the company’s acquisition and integration of ev3.
Before his time at Covidien, Joe served as Smith & Nephew’s global president, advanced wound management, and Alliance Imaging’s vice president, Pacific operations. He previously served as board director for Acelity, the Advanced Medical Technology Association (AdvaMed) and Systagenix Wound Management. He also served as Chair of AdvaMed’s Wound Healing and Tissue Regeneration Sector.
He holds a bachelor’s degree from California State University, Fullerton.